Páldyová Estera, Bereczki E, Sántha M, Wenger T, Borsodi Anna, Benyhe S
Institute of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary.
Acta Biol Hung. 2007;58 Suppl:113-29. doi: 10.1556/ABiol.58.2007.Suppl.9.
Numerous studies have shown functional links between the cannabinoid and opioid systems. The goal of this study was to evaluate whether acute treatments by endogenous cannabinoid agonist, selective CB1 or CB2 receptor antagonists modulate the expression of mu- (MOR) and delta- (DOR) opioid receptor mRNA levels and functional activity in the cerebellum of transgenic mice deficient in the CB1 type of cannabis receptors. We examined the effect of noladin ether (endogenous cannabinoid agonist) pretreatment on MOR and DOR mRNA expression by using reverse transcription and real-time polimerase chain reaction (PCR) and the ability of subsequent application of the opioid agonists to activate G-proteins, as measured by [35S]GTPgammaS binding, in wild-type (CB1+/+) and CB1 cannabinoid receptor deficient (CB1-/-, 'knockout', K.O.) mice. The acute administration of noladin ether markedly reduced MOR-mediated G-protein activation and caused a significant increase in the level of MOR mRNAs in the cerebella of wildtype, but not in the CB1-/- mice. No significant differences were observed in DOR functional activity and mRNA expression in wild-type animals. In CB1-/- mice the expression of DOR mRNA increased after noladin ether treatment, but no changes were found in DOR functional activity. In addition, Rimonabant (selective central cannabinoid CB1 receptor antagonist) and SR144528 (selective peripheral cannabinoid CB2 receptor antagonist) caused significant potentiation in MOR functional activity in the wild-type animals, whereas DOR mediated G-protein activation was increased in the CB1-/- mice. In contrast, Rimonabant and SR144528 decreased the MOR and DOR mRNA expressions in both CB1+/+ and CB1-/- mice. Taken together, these results indicate that acute treatment with cannabinoids causes alterations in MOR and DOR mRNA expression and functional activity in the cerebella of wild-type and CB1 knockout mice indicating indirect interactions between these two signaling systems.
众多研究表明大麻素系统和阿片系统之间存在功能联系。本研究的目的是评估内源性大麻素激动剂、选择性CB1或CB2受体拮抗剂的急性处理是否会调节CB1型大麻受体缺陷的转基因小鼠小脑内μ-(MOR)和δ-(DOR)阿片受体mRNA水平及功能活性。我们通过逆转录和实时聚合酶链反应(PCR)检测了诺拉汀醚(内源性大麻素激动剂)预处理对MOR和DOR mRNA表达的影响,并通过[35S]GTPγS结合来测量随后应用阿片激动剂激活G蛋白的能力,实验对象为野生型(CB1+/+)和CB1大麻素受体缺陷型(CB1-/-,“敲除”,K.O.)小鼠。诺拉汀醚的急性给药显著降低了野生型小鼠小脑中MOR介导的G蛋白激活,并导致野生型小鼠小脑中MOR mRNA水平显著升高,但在CB1-/-小鼠中未出现这种情况。在野生型动物中,DOR功能活性和mRNA表达未观察到显著差异。在CB1-/-小鼠中,诺拉汀醚处理后DOR mRNA表达增加,但DOR功能活性未发现变化。此外,利莫那班(选择性中枢大麻素CB1受体拮抗剂)和SR144528(选择性外周大麻素CB2受体拮抗剂)在野生型动物中导致MOR功能活性显著增强,而在CB1-/-小鼠中DOR介导的G蛋白激活增加。相反,利莫那班和SR144在CB1+/+和CB1-/-小鼠中均降低了MOR和DOR mRNA表达。综上所述,这些结果表明,大麻素的急性处理会导致野生型和CB1敲除小鼠小脑中MOR和DOR mRNA表达及功能活性发生改变,表明这两个信号系统之间存在间接相互作用。